
Triple hormone-pathway compound — information only. Contact us about availability.
Retatrutide 32mg Pen — retatrutide, a GLP-1, GIP and glucagon receptor agonist, supplied as a pre-filled pen. Information page only.
This Xenogenix product is labelled as containing 32mg retatrutide as a pre-filled pen. Retatrutide is a triple hormone receptor agonist acting on GLP-1, GIP and glucagon pathways, and is being studied for weight management and metabolic conditions. This page is for information only — it is not available to order online.
Retatrutide acts on GLP-1 receptors (appetite regulation and blood-glucose control), GIP receptors (insulin secretion and metabolic regulation) and glucagon receptors (energy metabolism).
Reported side effects in clinical trials include nausea, diarrhoea, vomiting and constipation. Long-term safety is still being investigated. Do not combine with other appetite-suppressant or glucose-lowering medications without medical supervision. Not suitable during pregnancy or breastfeeding.
It is not a routine weight-loss option for healthy, lean individuals and should not be used without appropriate medical oversight.
Discuss approved weight-management options with a qualified healthcare professional. No dosing guidance is given on this page.
Follow the manufacturer’s label for temperature range and expiry. Keep away from heat and light and out of children’s reach.
No. This is an information page only. Contact us to ask about availability.
Do not combine it with other appetite-suppressant or glucose-lowering medications without medical supervision.